Elevation of serum β2-microglobulin levels may reflect the amount of tumour in patients with haematologic malignancies, particularly multiple myeloma, and have been shown to be a very effective and independent indicator of survival in multiple myeloma [10], [11]. The gene discussed is HLA-G; the disease is AL amyloidosis.